Plagrin Plus

Indications of Plagrin Plus Tablet

Acute coronary syndrome (ACS): it is suitable for reducing the occurrence of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [Unstable angina (AI) / non-ST-segment elevation myocardial infarction (NSTEMI) ] Rate. It is used to reduce the incidence of myocardial infarction and stroke in patients with ST-elevation myocardial infarction (STEMI). 

 Recent MI, Recent Stroke, or Confirmed Peripheral Artery Disease: For patients with confirmed peripheral artery disease or recent myocardial infarction (MI) or a history of recent stroke, it can reduce the incidence of myocardial infarction and stroke.

 

Pharmacology of Plagrin Plus Tablet

Clopidogrel is a prodrug. It inhibits platelet activation and aggregation by irreversibly binding its active metabolites to P2Y12 ADP receptors on platelets. A dose-dependent inhibition of platelet aggregation can be observed 2 hours after a single oral administration. A repeated daily dose of 75 mg inhibited ADP-induced platelet aggregation on the first day, and the inhibition reached a steady state between the 3rd and the 7th day.

 

Dosage & Administration of Plagrin Plus Tablet

The recommended oral dose is one tablet daily.

 

Interactions of Plagrin Plus Tablet

NSAIDs, warfarin, selective serotonin and norepinephrine reuptake inhibitors (SSRIs, SNRIs): increase the risk of bleeding 
 

CYP2C19 inhibitors (omeprazole or esomeprazole): avoid simultaneous use of Ogilvy Prazole or Esomeprazole 
 

Repaglinide (using Repcomit2C substrate) increases the plasma concentration of Repaglinide

 

Contraindications

Clopidogrel is contraindicated in the following situations: Allergic to any component of the drug or product. Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.

 

Side-Effects of Plagrin Plus Tablet

Clopidogrel is usually a well-tolerated drug. 
 

Common side effects: bleeding, diarrhea, gastrointestinal discomfort, bleeding, skin reactions. 
 

Rare side effects: Acquired hemophilia, anemia, angioedema, joint pain, arthritis, bone marrow disease.

 

Pregnancy

There is no adequate and well-controlled study of pregnant women. It should be used during pregnancy only when clearly necessary. It is not known whether clopidogrel is excreted in human milk. The importance of the drug to the mother should be considered and a decision made to stop breastfeeding or discontinue the drug.

 

Precautions

Since it is a prodrug, the metabolism of its active metabolites is affected by CYP2C19 (weak metabolizer) gene mutations and drugs that inhibit CYP2C19 (such as omeprazole and esomeprazole).

Simultaneous use of these drugs and CYP2C19 weak metabolizers may reduce the antiplatelet activity of clopidogrel. 
 

Because it inhibits platelet aggregation during the entire life cycle (710 days) of platelets, it may increase the risk of bleeding. In order to restore hemostasis, platelet transfusion within 4 hours after the loading dose or within 2 hours after the maintenance dose may be less effective. 
 

Discontinuation of clopidogrel increases the risk of cardiovascular events.

Discontinue medication 5 days prior to elective surgery due to risk of severe bleeding.

Clopidogrel was restored immediately after hemostasis. 
 

Thrombotic thrombocytopenic purpura (TTP) is reported to require urgent treatment, including plasma exchange (plasma exchange). 
 

In patients receiving clopidogrel or patients with a history of allergies to other thienopyridines, allergies, including rash, angioedema, or haematological reactions have been reported.

 

Therapeutic Class

Anti-platelet drugs

 

Storage Conditions

Keep below 30°C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.

 

Pharmaceutical Name of Plagrin Plus Tablet

Renata Limited

 

Generic of Plagrin Plus Tablet

Clopidogrel + Aspirin